Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

The CDC has permanent leadership in place for the first time since August 2025, after the US Senate confirmed the appointment ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

A Netherlands-based compounding pharmacy has been ordered to stop distributing a compounded nasal spray formulation of Novo Nordisk's GLP-1 agonist semaglutide in a test of the country's pharmacy ...

Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

There is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, according to ...

Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...

News of the expanded cost-reduction drive came as Pfizer recorded 1% sales growth to $15 billion, driven by continued strong ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...